Humans have prevailed in the battle with most other species, including bacteria and viruses. The target of medical treatment has changed to systemic diseases that occur without provocation, such as cancers and degenerative diseases.
As an ophthalmologist, when I examine patients with incurable diseases, I always hope to relieve their suffering, but often have a sense of helplessness. One day, Dr. Yoshimura, a professor in the department of ophthalmology at Kyoto University, challenged me to start a bio-venture company. I founded KDDD (Kyoto Drug Discovery & Development Co., Ltd.), which remains affiliated and collaborates with Kyoto University.
KDDD develops KUSs (Kyoto University Substances). The first inventor of a product is Dr. Kakizuka, professor in the graduate school of biostudies at Kyoto University; the second inventor is Dr. Ikeda, associate professor at Kyoto University Hospital. KUSs are novel compounds that improve ATP consumption by inhibiting the ATPase of VCP and protect cells from a lot of kind of damages, such as degeneration and ischemic damage. In animal models, KUSs have neuroprotective effects for chronic degenerative diseases such as retinitis pigmentosa and glaucoma. Our mission is to develop KUSs for treatment of patients with incurable eye disease. As KUSs have a unique mechanism, they may also provide strong cell-protective effects in other diseases.
Our Mission
- strong passion to develop and make drugs available for incurable diseases
- strong social responsibility
- gratitude to society, academia, and the medical field
We promise a sincere commitment to global health.
Our mission is to supply effective drugs for current and future patients with incurable diseases.
We are dedicated to bringing smiles to patients around the world.
| Corporate name | Kyoto Drug Discovery & Development Co., Ltd. |
|---|---|
| Head Office | 8F , DP Square Sakaisuji Honmachi 1-6-9 , Awaji-Machi , Chuo-ku , Osaka , 541-0047 JAPAN |
| Labo | #302, Saito Bio Hills Center 7-7-18,Saitoasagi,Ibaraki-city,Osaka,567-0085 JAPAN |
| President & CEO | Sakae Muto |
| Major Business Activities | Research and Development of Drug, Diagnostic Drug, Human Cell Therapy and Gene therapy Products, Medical Equipment, Medical Instruments, Reagent and Medical Supplies |
| Establishment | May 15th. 2015 |
| Account Closing Month | April |
| Capital | 69.6 million yen(as of April 30, 2022) |
| Our Bank | Bank of Tokyo-Mitsubishi UFJ, Toji Branch Sumitomo Mitsui Banking Corporation, Kyoto Branch |
February 17th, 2022
Lab moves into Saito Bio Hills Center
July 15th, 2021
Headquarters moves into Chuo-ku, Osaka
August 1st, 2017
Labo was established in a building in Kyoto University
September 27th, 2016
Headquarters moves into a building in Kyoto University
March 30th, 2016
License Agreement with Kyoto University
May 15th, 2015
Established
| CEO | Sakae Muto |
| CMO | Kunihiro Musashi M.D. Ph.D. |
| CTO | Masaki Okamoto Ph.D. |
| Director | Nobuhiro Yagi Ph.D. |
| Auditor | Shinichi Kotani |
